NO314537B1 - Reseptorbindende konjugater - Google Patents
Reseptorbindende konjugater Download PDFInfo
- Publication number
- NO314537B1 NO314537B1 NO19995978A NO995978A NO314537B1 NO 314537 B1 NO314537 B1 NO 314537B1 NO 19995978 A NO19995978 A NO 19995978A NO 995978 A NO995978 A NO 995978A NO 314537 B1 NO314537 B1 NO 314537B1
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- folate
- conjugate
- radionuclide
- stated
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 45
- 102000005962 receptors Human genes 0.000 title claims abstract description 17
- 108020003175 receptors Proteins 0.000 title claims abstract description 17
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 120
- 239000011724 folic acid Substances 0.000 claims abstract description 104
- 235000019152 folic acid Nutrition 0.000 claims abstract description 100
- 229940014144 folate Drugs 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000009977 dual effect Effects 0.000 claims abstract description 9
- 239000003186 pharmaceutical solution Substances 0.000 claims abstract 4
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims description 38
- 229960000304 folic acid Drugs 0.000 claims description 25
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000002372 labelling Methods 0.000 claims description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical group CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003708 ampul Substances 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002600 positron emission tomography Methods 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 238000001879 gelation Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000002224 folic acids Chemical class 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 48
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 201000008968 osteosarcoma Diseases 0.000 description 8
- 238000000159 protein binding assay Methods 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000000163 radioactive labelling Methods 0.000 description 6
- 229940051022 radioimmunoconjugate Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012217 radiopharmaceutical Substances 0.000 description 4
- 229940121896 radiopharmaceutical Drugs 0.000 description 4
- 230000002799 radiopharmaceutical effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940044173 iodine-125 Drugs 0.000 description 2
- AMZMQXJQIYKBJU-UHFFFAOYSA-N iodo benzoate Chemical compound IOC(=O)C1=CC=CC=C1 AMZMQXJQIYKBJU-UHFFFAOYSA-N 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO19995978A NO314537B1 (no) | 1999-12-06 | 1999-12-06 | Reseptorbindende konjugater |
| AT00980133T ATE505208T1 (de) | 1999-12-06 | 2000-12-05 | Rezeptorbindende konjugate |
| DK00980133.3T DK1237584T3 (da) | 1999-12-06 | 2000-12-05 | Receptorbindende konjugater |
| JP2001541537A JP5153044B2 (ja) | 1999-12-06 | 2000-12-05 | レセプターに結合する複合体 |
| PCT/NO2000/000413 WO2001039806A1 (fr) | 1999-12-06 | 2000-12-05 | Conjugues de liaison au recepteur |
| PT00980133T PT1237584E (pt) | 1999-12-06 | 2000-12-05 | Conjugados de liga??o a receptor |
| US09/731,301 US6740304B2 (en) | 1999-12-06 | 2000-12-05 | Receptor binding conjugates |
| ES00980133T ES2364811T3 (es) | 1999-12-06 | 2000-12-05 | Conjugados de unión con un re. |
| AU17432/01A AU1743201A (en) | 1999-12-06 | 2000-12-05 | Receptor binding conjugates |
| EP00980133A EP1237584B1 (fr) | 1999-12-06 | 2000-12-05 | Conjugues de liaison au recepteur |
| DE60045847T DE60045847D1 (de) | 1999-12-06 | 2000-12-05 | Rezeptorbindende konjugate |
| US10/766,057 US20040184990A1 (en) | 1999-12-06 | 2004-01-28 | Receptor binding conjugates |
| US14/571,524 US20150258223A1 (en) | 1999-12-06 | 2014-12-16 | Receptor binding conjugates |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO19995978A NO314537B1 (no) | 1999-12-06 | 1999-12-06 | Reseptorbindende konjugater |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO995978D0 NO995978D0 (no) | 1999-12-06 |
| NO995978L NO995978L (no) | 2001-06-07 |
| NO314537B1 true NO314537B1 (no) | 2003-04-07 |
Family
ID=19904060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19995978A NO314537B1 (no) | 1999-12-06 | 1999-12-06 | Reseptorbindende konjugater |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6740304B2 (fr) |
| EP (1) | EP1237584B1 (fr) |
| JP (1) | JP5153044B2 (fr) |
| AT (1) | ATE505208T1 (fr) |
| AU (1) | AU1743201A (fr) |
| DE (1) | DE60045847D1 (fr) |
| DK (1) | DK1237584T3 (fr) |
| ES (1) | ES2364811T3 (fr) |
| NO (1) | NO314537B1 (fr) |
| PT (1) | PT1237584E (fr) |
| WO (1) | WO2001039806A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
| NO314537B1 (no) * | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
| NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| WO2002087424A2 (fr) * | 2001-05-02 | 2002-11-07 | Purdue Research Foundation | Traitement et diagnostic de maladies associees aux macrophages |
| US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US8043603B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| GR1004274B (el) * | 2002-07-16 | 2003-06-23 | Medexis ���� | Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες |
| BR0312690A (pt) | 2002-07-16 | 2005-05-03 | Medexis S A | Conjugados esteróides, sua preparação e seu uso |
| EP1617876B1 (fr) * | 2003-04-15 | 2014-05-14 | Algeta AS | Thorium 227 utilisable en radiotherapie pour traiter une maladie des tissus mous |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| CA2527196C (fr) | 2003-05-30 | 2012-10-16 | Purdue Research Foundation | Procede de diagnostic de l'atherosclerose |
| EP1735013B1 (fr) * | 2004-02-20 | 2012-02-08 | Algeta ASA | Particules d'hydroxyapatite emettrices de rayons alpha et beta |
| GB0423565D0 (en) * | 2004-10-22 | 2004-11-24 | Algeta As | Formulation |
| CA2592302C (fr) * | 2004-12-23 | 2013-10-29 | Purdue Research Foundation | Procede d'imagerie par tomographie par emission de positrons |
| JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| EP1940473A2 (fr) | 2005-09-23 | 2008-07-09 | Purdue Research Foundation | Procede et dispositif de cytometrie en flux in vivo |
| US8486412B2 (en) | 2006-06-01 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
| EP2087337A4 (fr) | 2006-11-03 | 2010-09-08 | Purdue Research Foundation | Procédé de cytométrie en flux<i>ex vivo</i>et dispositif |
| AU2008213702B2 (en) | 2007-02-07 | 2014-04-24 | Purdue Research Foundation | Positron emission tomography imaging method |
| US8961926B2 (en) | 2007-05-25 | 2015-02-24 | Purdue Research Foundation | Method of imaging localized infections |
| CN101985471B (zh) * | 2009-07-29 | 2014-04-30 | 上海汉升生物科技有限公司 | 叶酸-IgG偶联物及其制备方法与应用 |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201122325D0 (en) | 2011-12-23 | 2012-02-01 | Cytoguide As | Novel formulations |
| PL3157577T3 (pl) | 2014-06-18 | 2021-04-19 | Alpha Therapy Solutions Ab | Automatyczna platforma technologii produkcji radiofarmaceutyków astatyna-211 [at-211] |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336185A (en) | 1976-03-02 | 1982-06-22 | Rohm And Haas Company | Folic acid derivatives |
| DE3436177A1 (de) * | 1984-10-03 | 1986-04-03 | Goldschmidt Ag Th | Verwendung von polyoxyalkylen-polysiloxan-copolymerisaten mit an siliciumatomen gebundenen langkettigen alkylresten als emulgatoren zur herstellung von w/o-emulsionen |
| EP0282057A3 (fr) * | 1987-03-11 | 1990-03-07 | The Board Of Regents Of The University Of Michigan | Produits associés chémo-radio-immunologiques |
| US5686578A (en) * | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| US5547668A (en) * | 1995-05-05 | 1996-08-20 | The Board Of Trustees Of The University Of Illinois | Conjugates of folate anti-effector cell antibodies |
| WO1997041898A1 (fr) * | 1996-05-03 | 1997-11-13 | Immunomedics, Inc. | Immunotherapie-cible associee contre le cancer |
| US6093382A (en) * | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
| NO314537B1 (no) * | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
| NO312708B1 (no) * | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| GB0213261D0 (en) * | 2002-06-10 | 2002-07-17 | Anticancer Therapeutic Inv Sa | Method |
| US20060228297A1 (en) * | 2003-04-15 | 2006-10-12 | Roy Larsen | Thorium-227 for use in radiotherapy of soft tissue disease |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
-
1999
- 1999-12-06 NO NO19995978A patent/NO314537B1/no not_active IP Right Cessation
-
2000
- 2000-12-05 AT AT00980133T patent/ATE505208T1/de active
- 2000-12-05 DK DK00980133.3T patent/DK1237584T3/da active
- 2000-12-05 EP EP00980133A patent/EP1237584B1/fr not_active Expired - Lifetime
- 2000-12-05 DE DE60045847T patent/DE60045847D1/de not_active Expired - Lifetime
- 2000-12-05 PT PT00980133T patent/PT1237584E/pt unknown
- 2000-12-05 JP JP2001541537A patent/JP5153044B2/ja not_active Expired - Fee Related
- 2000-12-05 ES ES00980133T patent/ES2364811T3/es not_active Expired - Lifetime
- 2000-12-05 US US09/731,301 patent/US6740304B2/en not_active Expired - Lifetime
- 2000-12-05 AU AU17432/01A patent/AU1743201A/en not_active Abandoned
- 2000-12-05 WO PCT/NO2000/000413 patent/WO2001039806A1/fr active Application Filing
-
2004
- 2004-01-28 US US10/766,057 patent/US20040184990A1/en not_active Abandoned
-
2014
- 2014-12-16 US US14/571,524 patent/US20150258223A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1237584A1 (fr) | 2002-09-11 |
| DK1237584T3 (da) | 2011-07-18 |
| DE60045847D1 (de) | 2011-05-26 |
| ES2364811T3 (es) | 2011-09-14 |
| US20040184990A1 (en) | 2004-09-23 |
| PT1237584E (pt) | 2011-05-02 |
| EP1237584B1 (fr) | 2011-04-13 |
| US20150258223A1 (en) | 2015-09-17 |
| ATE505208T1 (de) | 2011-04-15 |
| JP5153044B2 (ja) | 2013-02-27 |
| JP2003515570A (ja) | 2003-05-07 |
| NO995978L (no) | 2001-06-07 |
| NO995978D0 (no) | 1999-12-06 |
| US20010008625A1 (en) | 2001-07-19 |
| WO2001039806A1 (fr) | 2001-06-07 |
| US6740304B2 (en) | 2004-05-25 |
| AU1743201A (en) | 2001-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO314537B1 (no) | Reseptorbindende konjugater | |
| RU2560587C9 (ru) | Новые радиоиммуноконъюгаты и их применения | |
| Ahlgren et al. | Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules | |
| CA2873144C (fr) | Complexes radiopharmaceutiques | |
| Tolmachev et al. | Targeted nuclear medicine. Seek and destroy | |
| US20110117012A1 (en) | Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors | |
| Guleria et al. | Formulation and clinical translation of [177 Lu] Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer | |
| Henriksen et al. | Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies | |
| KR20240035757A (ko) | 우로키나제 플라스미노겐 활성화제 수용체-표적화된 방사성 약제 | |
| JPH05501107A (ja) | 画像用放射標識抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |